The era of precision medicine is nigh. Plummeting costs of genetic testing; rapid advances in computational power; massive, linked databases; and new targeted therapies are making it increasingly ...

NEW YORK – Sanofi on Monday said it will acquire Blueprint Medicines, adding the firm's immunology and oncology drug Ayvakit (avapritinib) along with investigational treatments for rare diseases and ...

The talk, presented by Dr. Kevin Flanagan (Cofactor’s VP of Translational Science), “Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform”, highlighted OncoPrism’s ...

SAN FRANCISCO--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for Parkinson’s disease (PD), today announced the launch of a clinical program with Parkinson’s Foundation to ...

For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with persistent undertreatment of high-risk older patients with effective ...

NEW YORK – Fore Biotherapeutics announced Wednesday that it has raised $38 million in its latest round of financing, which it will put toward developing its lead asset plixorafenib, a BRAF inhibitor.

BETHESDA, Md., May 20, 2025 /PRNewswire/ -- Precision for Medicine, an operating unit of Precision Medicine Group and a leading next-generation provider of drug development and commercialization ...